Targeting nicotine addiction: the possibility of a therapeutic vaccine
Por:
Escobar-Chavez, JJ, Dominguez-Delgado, CL, Rodriguez-Cruz, IM
Publicada:
18 abr 2011
Resumen:
Cigarette smoking is the primary cause of lung cancer, cardiovascular diseases, reproductive disorders, and delayed wound healing all over the world. The goals of smoking cessation are both to reduce health risks and to improve quality of life. The development of novel and more effective medications for smoking cessation is crucial in the treatment of nicotine dependence. Currently, first-line smoking cessation therapies include nicotine replacement products and bupropion. The partial nicotinic receptor agonist, varenicline, has recently been approved by the US Food and Drug Administration (FDA) for smoking cessation. Clonidine and nortriptyline have demonstrated some efficacy, but side effects may limit their use to second-line treatment products. Other therapeutic drugs that are under development include rimonabant, mecamylamine, monoamine oxidase inhibitors, and dopamine D3 receptor antagonists. Nicotine vaccines are among newer products seeking approval from the FDA. Antidrug vacci
Filiaciones:
Escobar-Chavez, JJ:
Univ Nacl Autonoma Mexico, Unidad Invest Multidisciplinaria, Fac Estudios Super Cuautitlan, Lab 12, Cuautitlan 54714, Estado De Mexic, Mexico
Dominguez-Delgado, CL:
Univ Nacl Autonoma Mexico, Div Estudios Posgrad Tecnol Farmaceut, Fac Estudios Super Cuautitlan, Cuautitlan 54714, Estado De Mexic, Mexico
Rodriguez-Cruz, IM:
Univ Nacl Autonoma Mexico, Div Estudios Posgrad Tecnol Farmaceut, Fac Estudios Super Cuautitlan, Cuautitlan 54714, Estado De Mexic, Mexico
|